ADAM9 Antibody (15): sc-135822
- ADAM9 Antibody (15) is a mouse monoclonal IgG1, cited in 1 publications, provided at 50 µg/500 µl
- raised against amino acids 86-227 of ADAM9 of human origin
- recommended for detection of ADAM9 of mouse, rat and human origin by WB, IP and IF; not recommended for IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for ADAM9 Antibody (15). This work is in progress.
ADAM9 Antibody (15) is a mouse monoclonal IgG1 antibody that detects ADAM9 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). ADAM9 is a member of the ADAM (a disintegrin and metalloprotease) family, which consists of over 30 membrane-anchored, zinc-dependent proteases that play crucial roles in various biological processes, including fertilization, muscle fusion, and cytokine secretion. ADAM9 is primarily located on the cell surface, where ADAM9 participates in cell adhesion and signaling events, making ADAM9 essential for maintaining cellular communication and tissue integrity. ADAM9′s presence in tissues such as the brain, liver, heart, kidney, lung, and trachea highlights ADAM9′s importance in both normal physiological functions and potential pathological conditions. ADAM9′s structure includes several functional domains: a signal domain for secretion, a pro domain that regulates activity, a metalloprotease domain for enzymatic function, a disintegrin domain that interacts with integrins, and an epidermal growth factor-like domain that may influence cell signaling pathways. Understanding ADAM9′s structural features is vital, as these features dictate interactions with other proteins and overall role in cellular processes. Anti-ADAM9 antibody (15) is an invaluable tool for researchers investigating the multifaceted roles of this protein in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ADAM9 Antibody (15) References:
- The pleiotropic roles of ADAM9 in the biology of solid tumors. | Oria, VO., et al. 2018. Cell Mol Life Sci. 75: 2291-2301. PMID: 29550974
- The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer. | Le, TT., et al. 2022. Am J Cancer Res. 12: 176-197. PMID: 35141012
- Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. | Scribner, JA., et al. 2022. Mol Cancer Ther. 21: 1047-1059. PMID: 35511740
- IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD. | Li, D., et al. 2022. Int J Chron Obstruct Pulmon Dis. 17: 2589-2602. PMID: 36267325
- The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. | Chang, AC., et al. 2023. Int J Biol Sci. 19: 760-771. PMID: 36778124
- Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. | Huang, YK., et al. 2024. Nat Cancer. 5: 400-419. PMID: 38267627
- ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. | Bazzone, LE., et al. 2024. Nat Commun. 15: 4153. PMID: 38755212
- Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells, Which Enhances Transforming Growth Factor β1 Activation and Promotes Tissue Fibrosis in Patients With Lupus Nephritis. | Umeda, M., et al. 2025. Arthritis Rheumatol. 77: 180-189. PMID: 39279154
- Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches. | Jiang, L., et al. 2024. Sci Rep. 14: 26432. PMID: 39488509
- A pan-cancer study of ADAM9's immunological function and prognostic value particularly in liver cancer. | AmeliMojarad, M., et al. 2024. Sci Rep. 14: 26862. PMID: 39505907
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ADAM9 Antibody (15) | sc-135822 | 50 µg/500 µl | $322.00 |